Published in J Virol on January 01, 2004
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Frequency and implications of HIV superinfection. Lancet Infect Dis (2013) 1.19
HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One (2009) 1.16
Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. Retrovirology (2009) 1.03
Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology (2012) 0.95
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology (2007) 0.83
Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation. Retrovirology (2010) 0.79
A Multi-Vector, Multi-Envelope HIV-1 Vaccine. J Pediatr Pharmacol Ther (2007) 0.78
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary? AIDS Res Ther (2005) 0.78
HIV competition dynamics over sexual networks: first comer advantage conserves founder effects. PLoS Comput Biol (2015) 0.76
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol (1993) 6.41
Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA (1994) 5.60
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet (2001) 5.28
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci U S A (1996) 2.57
Escape of human immunodeficiency virus from immune control. Annu Rev Immunol (1997) 2.52
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol (1992) 2.41
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology (1997) 2.03
Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS (2002) 1.96
HIV: current opinion in escapology. Curr Opin Microbiol (2002) 1.86
Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor. J Virol (1995) 1.85
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol (2002) 1.80
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A (1993) 1.77
Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS (2002) 1.70
Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J Virol (1997) 1.62
Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis (1995) 1.58
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo. J Virol (1991) 1.55
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology (1999) 1.54
Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs. J Clin Microbiol (1998) 1.53
Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS (2003) 1.52
Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods (1997) 1.50
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol (2002) 1.50
Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol (1987) 1.47
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis (2003) 1.42
Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS (2001) 1.40
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS (2002) 1.40
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes (1996) 1.33
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol (1997) 1.30
HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses circulating among injecting drug users. AIDS (2001) 1.25
Spatial discontinuities in human immunodeficiency virus type 1 quasispecies derived from epidermal Langerhans cells of a patient with AIDS and evidence for double infection. J Virol (1994) 1.18
Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr (2002) 1.17
Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences. J Gen Virol (2002) 1.15
Position and degree of mismatches and the mobility of DNA heteroduplexes. Nucleic Acids Res (2000) 1.14
Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis (1999) 1.12
Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis (1999) 1.11
Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. J Virol (1995) 1.09
Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. Immunol Rev (2001) 1.06
Identification of diverse HIV type 1 subtypes and dual HIV type 1 infection in pregnant Ugandan women. AIDS Res Hum Retroviruses (2000) 1.04
Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection. J Virol (2002) 1.04
Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med (1995) 1.00
Apparent founder effect during the early years of the San Francisco HIV type 1 epidemic (1978-1979). AIDS Res Hum Retroviruses (2000) 0.99
Recent evolutionary history of human immunodeficiency virus type 1 subtype B: reconstruction of epidemic onset based on sequence distances to the common ancestor. J Mol Evol (2002) 0.97
Triple HIV-1 infection with group O and Group M of different clades in a single Cameroonian AIDS patient. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.93
HIV-1 gp120 sequences from a doubly infected drug user. AIDS Res Hum Retroviruses (1995) 0.91
Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection. J Virol (1995) 0.86
Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America. Virology (2000) 0.85
Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251. Virology (1996) 0.84
Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS (1999) 0.84
Presence of multiple HIV subtypes and a high frequency of subtype chimeric viruses in heterosexually infected women. J Acquir Immune Defic Syndr (1999) 0.83
Superinfection with human immunodeficiency virus type 2 can reactivate virus production in baboons but is contained by a CD8 T cell antiviral response. J Infect Dis (1997) 0.80
Molecular characterization of a recombinant HIV type 1 isolate (A/G/E/?): unidentified regions may be derived from parental subtype E sequences. AIDS Res Hum Retroviruses (2000) 0.79
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis (2001) 0.76
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Age affects outcomes in chronic kidney disease. J Am Soc Nephrol (2007) 5.36
Association of journal quality indicators with methodological quality of clinical research articles. JAMA (2002) 5.13
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med (2008) 3.64
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
Rapid identification of known and new RNA viruses from animal tissues. PLoS Pathog (2008) 3.54
The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol (2013) 3.37
Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog (2009) 3.35
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS (2006) 2.72
Physician predictors of mammographic accuracy. J Natl Cancer Inst (2005) 2.72
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
New adenovirus species found in a patient presenting with gastroenteritis. J Virol (2007) 2.63
Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health (2005) 2.56
The fecal viral flora of wild rodents. PLoS Pathog (2011) 2.51
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol (2010) 2.37
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med (2007) 2.36
Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35
Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med (2007) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
A novel picornavirus associated with gastroenteritis. J Virol (2009) 2.25
Cardioviruses are genetically diverse and cause common enteric infections in South Asian children. J Virol (2009) 2.23
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia. Ann Emerg Med (2007) 2.18
White/black racial differences in risk of end-stage renal disease and death. Am J Med (2009) 2.16
Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust (2006) 2.14
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis (2006) 2.06
Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr (2008) 2.05
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend (2003) 1.99
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health (2003) 1.97
Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health (2003) 1.96
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 1.94
The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr (2008) 1.94
Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA (2006) 1.90
Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis (2011) 1.90
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS (2002) 1.87
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Frequency of trigeminal nerve injuries following third molar removal. J Oral Maxillofac Surg (2005) 1.84
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis (2003) 1.82
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood (2012) 1.81
The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A (2013) 1.80
HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health (2005) 1.77
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis (2005) 1.76
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol (2002) 1.74
Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol (2003) 1.73
Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat Appl Genet Mol Biol (2004) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med (2005) 1.69
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68
High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation (2004) 1.68
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS (2003) 1.66
Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant (2003) 1.65
Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr (2008) 1.63
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis (2007) 1.62
The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr (2007) 1.62
Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach. PLoS Med (2006) 1.62
Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis (2003) 1.62
Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis (2006) 1.61
Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol (2010) 1.60
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol (2007) 1.57
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57
The impact of Medicaid managed care on hospitalizations for ambulatory care sensitive conditions. Health Serv Res (2005) 1.55